Open Nav

参麦注射液对乳腺癌患者术后患者的血清PCT、IL-6、TNF-α水平及心肌功能的

以下是资料介绍,如需要完整的请充值下载.
1.无需注册登录,支付后按照提示操作即可获取该资料.
2.资料以网页介绍的为准,下载后不会有水印.仅供学习参考之用.
   帮助中心
资料介绍:

参麦注射液对乳腺癌患者术后患者的血清PCT、IL-6、TNF-α水平及心肌功能的影响(论文5600字)
【摘要】 目的 研究参麦注射液对乳腺癌患者术后患者的血清PCT、IL-6、TNF-α水平及心肌功能的影响,并评价其改善预后的效果。方法 收集2014年3月至2016年12月我院的90例乳腺癌患者。按抽签法分为实验组和对照组,每组45例。两组患者在术后均进行化疗治疗,静脉滴注环磷酰胺、氟尿嘧啶、表柔比星。实验组在此基础上,采用参麦注射液治疗,每次50ml,加入5%葡萄糖注射液500ml中进行静脉滴注,每天1次。观察两组治疗疗效,临床症状积分,降钙素原(PCT)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平,肌钙蛋白(cTnI)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)水平,超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)、丙二醛(MDA)水平。结果 实验组总缓解率显著高于对照组[86.66%(39/45)vs66.66%(30/45)](P<0.05);乏力、自汗、口咽干燥、神疲积分均显著低于对照组[(1.53±0.23)分 vs(3.10±0.63)分,(1.40±0.32)分 vs(3.15±0.80)分,(1.30±0.31)分 vs(3.04±0.70)分,(1.52±0.27)分 vs(3.02±0.60)分](P<0.05);PCT、IL-6、TNF-α水平显著低于对照组[(1.62±0.32)μg/L vs(5.83±1.05)μg/L,(5.72±0.98)pg/mL vs(10.89±1.52)pg/mL,(1.23±0.15)ng/mL vs(2.79±0.23)ng/mL](P<0.05);cTnI、CK、CK-MB水平显著低于对照组[(450.76±58.83)ng/L vs(702.17±83.18)ng/L,(1.87±0.40)IU/mL vs(5.20±1.34)IU/mL,(158.90±42.10)IU /L vs(910.38±97.94)IU /L](P<0.05);SOD、GSH水平显著高于对照组[(109.89±13.68)μIU /L vs(78.89±10.29)μIU /L,(140.83±20.82)μg/L vs(117.49±17.89)μg/L](P<0.05),MDA水平显著低于对照组[(5.39±1.21)μmol/L vs(12.76±3.81)μmol/L](P<0.05)。结论 参麦注射液对乳腺癌患者术后心肌保护具有显著的作用,可降低炎症因子PCT、IL-6、TNF-α水平,减少术后感染发生,有利于患者的预后。

[来源:http://Doc163.com]


【关键词】参麦注射液 乳腺癌 心肌功能 降钙素原 白细胞介素-6 肿瘤坏死因子-α
中图分类号:R737.9   文献标识码:A    文章编号:
Effect of Shenmai injection on serum PCT, IL-6, TNF-α and myocardial function in postoperative patients with breast cancer
[Abstract] Objective To study the effects of Shenmai injection on serum PCT, IL-6, TNF-α and myocardial function in postoperative patients with breast cancer and to evaluate its effect on prognosis.. Methods 90 patients of mammary cancer who received therapy from March 2014 to December 2016 in our hospital were selected as research objects. According to draw method were divided into the experimental group and the control group. Two groups of patients were treated with chemotherapy after operation, Intravenous infusion of cyclophosphamide, fluorouracil, epirubicin. The experimental group on this basis, was treated with Shenmai Injection, each 50ml, add 5% Glucose Injection 500ml to the intravenous drip, 1 times a day. Then the curative effect, clinical symptom score, procalcitonin (PCT) and interleukin -6 (IL-6), tumor necrosis factor alpha (TNF- alpha) levels of troponin (cTnI), creatine kinase (CK), creatine kinase (CK-MB) level, superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA) level of two groups were compared. Results The total remission rate of the experimental group was significantly higher than the control group[86.66%(39/45)vs66.66%(30/45)](P<0.05); Fatigue, sweating, dry mouth and throat, spiritlessness scores were significantly lower than the control group[(1.53±0.23)scores vs(3.10±0.63)scores,(1.40±0.32)scores vs(3.15±0.80)scores,(1.30±0.31)scores vs(3.04±0.70)scores,(1.52±0.27)scores vs(3.02±0.60)scores](P<0.05); PCT、IL-6、TNF-α level were significantly lower than the control group[(1.62±0.32)μg/L vs(5.83±1.05)μg/L,(5.72±0.98)pg/mL vs(10.89±1.52)pg/mL,(1.23±0.15)ng/mL vs(2.79±0.23)ng/mL](P<0.05); cTnI、CK、CK-MB level were significantly lower than the control group[(450.76±58.83)ng/L vs(702.17±83.18)ng/L,(1.87±0.40)IU/mL vs(5.20±1.34)IU/mL,(158.90±42.10)IU /L vs(910.38±97.94)IU /L](P<0.05);SOD、GSH level were significantly higher than the control group[(109.89±13.68)μIU /L vs(78.89±10.29)μIU /L,(140.83±20.82)μg/L vs(117.49±17.89)μg/L](P<0.05), MDA level were significantly lower than the control group[(5.39±1.21)μmol/L vs(12.76±3.81)μmol/L](P<0.05). [版权所有:http://DOC163.com]
Conclusion Shenmai injection has remarkable effect on myocardial protection after operation for breast cancer patients. It can reduce the levels of inflammatory factors PCT, IL-6 and TNF- alpha, reduce the incidence of postoperative infection and benefit the prognosis of patients.
Key words: Shenmai Injection, mammary cancer, myocardial function, procalcitonin, interleukin -6, tumor necrosis factor alpha
Chinese Library Classification(CLC): R737.9   Document code: A

[资料来源:http://www.doc163.com]

  • 关于资料
    提供的资料属本站所有,真实可靠,确保下载的内容与网页资料介绍一致.
  • 如何下载
    提供下载链接或发送至您的邮箱,资料可重复发送,若未收到请联系客服.
  • 疑难帮助
    下载后提供一定的帮助,收到资料后若有疑难问题,可联系客服提供帮助.
  • 关于服务
    确保下载的资料和介绍一致,如核实与资料介绍不符,可申请售后.
  • 资料仅供参考和学习交流之用,请勿做其他非法用途,转载必究,如有侵犯您的权利或有损您的利益,请联系本站,经查实我们会立即进行修正! 版权所有,严禁转载
    doc163.com Copyright © 2012-2024 苏ICP备2021029856号-4